AbbVie (ABBV) 주식 개요
는 연구 기반 바이오 제약 회사로 전 세계에서 의약품 및 치료제의 연구 개발, 제조, 상용화 및 판매에 종사하고 있습니다. 자세히 보기
ABBV Community Fair Values
Create NarrativeSee what 445 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Pharmaceuticals & Biotech opportunity
AbbVie Inc. 경쟁사
가격 이력 및 성과
| 과거 주가 | |
|---|---|
| 현재 주가 | US$202.71 |
| 52주 최고가 | US$244.81 |
| 52주 최저가 | US$176.57 |
| 베타 | 0.30 |
| 1개월 변동 | -1.77% |
| 3개월 변동 | -9.27% |
| 1년 변동 | 9.23% |
| 3년 변동 | 38.28% |
| 5년 변동 | 73.85% |
| IPO 이후 변동 | 479.17% |
최근 뉴스 및 업데이트
Recent updates
Seeking Alpha • Apr 30
AbbVie: Balancing Potential Acquisition Impact With Positive Q1 2026 Earnings
Summary AbbVie's price might have been sluggish in 2026 so far, but can the latest results change anything? Yes and no. No, because there's acquisition talk doing the rounds, which can be an earnings drag for now, even though it can be positive for revenues. Yes, because the latest results for Q1 2026 are good, with double-digit percent revenue growth and a healthy adjusted EPS rise too. The market multiples also look improved. ABBV's dividend yield is also encouraging, and together with market multiples, it indicates that the stock would hold investors in good stead over the long term. Read the full article on Seeking Alpha
내러티브 업데이트 • Apr 23
ABBV: Future Returns Will Rely On Immunology Expansion And Operating Leverage Execution
Analysts made a small upward adjustment to AbbVie’s fair value estimate to about $249. The modest change reflects a mix of slightly higher assumed discount rates and future P/E multiples, alongside recent shifts in Street price targets, including both raises and trims from firms such as Piper Sandler, Guggenheim, Cantor Fitzgerald, Evercore ISI, Citi and UBS, as well as fresh bullish initiations from Canaccord, RBC Capital and Barclays.내러티브 업데이트 • Apr 08
ABBV: Future Returns Will Hinge On Immunology Encore And Operating Leverage Execution
Analysts have made a modest upward adjustment to AbbVie’s price target, reflecting updated views on its immunology pipeline potential, operating leverage, and the ongoing debate about whether recent share underperformance and selloffs adequately reflect competitive risks. Analyst Commentary Recent research on AbbVie highlights a split view, with some analysts focusing on the upside from the immunology pipeline and operating leverage, while others point to valuation and competitive questions after a period of share underperformance.내러티브 업데이트 • Mar 24
ABBV: Future Returns Will Hinge On Immunology Encore Outweighing Competitive Concerns
Narrative Update The analyst price target for AbbVie has been adjusted slightly higher to reflect a fair value move to about $249. Analysts point to early stage indication expansion, operating leverage potential, and ongoing immunology pipeline developments, even as some firms flag emerging competition and a more balanced risk and reward profile.내러티브 업데이트 • Mar 10
ABBV: Future Returns Will Depend On Immunology Encore And Deal Optionality Uncertainty
The analyst price target for AbbVie edges higher to align with our fair value shift from $248.29 to $248.86, as analysts highlight ongoing indication expansion in immunology, potential operating leverage, and multiple expansion drivers, even as some firms note emerging competition and a more balanced risk and reward profile. Analyst Commentary Recent research on AbbVie reflects a split view, with some analysts pointing to upside tied to immunology growth and pipeline execution, while others flag competition risk and a more balanced risk and reward profile at current levels.
새 내러티브 • Mar 01
AbbVie Inc. (ABBV): The Immunology Powerhouse – Successfully Navigating the Post-Humira Transition
AbbVie (ABBV) has entered 2026 as a masterclass in pharmaceutical "lifecycle management," having effectively neutralized the long-feared "patent cliff" of its flagship drug, Humira. As of the February 27, 2026 close, the stock is trading at $232.03 , following a robust 3.3% single-day gain that capped off a volatile but ultimately bullish month.내러티브 업데이트 • Feb 22
ABBV: Future Returns Will Rely On Immunology Encore And Evolving Deal Optionality
Our updated AbbVie narrative reflects a modest price target increase to about $248 per share, as analysts point to potential operating leverage, room for P/E multiple expansion, and a pipeline of proof-of-concept and immunology programs that could support slightly higher revenue growth assumptions, even as margin expectations are trimmed. Analyst Commentary Recent research shows a mix of optimism and caution around AbbVie, with several firms adjusting price targets and ratings as they reassess execution risks, competitive pressures, and the potential impact of the pipeline on valuation.내러티브 업데이트 • Feb 07
ABBV: Future Returns Will Depend On Immunology Pipeline Clarity And M&A Uncertainty
Analysts have trimmed their price targets for AbbVie by a small amount. This reflects slightly lower revenue growth and P/E assumptions, while also incorporating a modestly higher profit margin and recent mixed research views around competition and pipeline visibility.내러티브 업데이트 • Jan 24
ABBV: Future Returns Will Hinge On Post-Humira Immunology And Deal Optionality
Analysts have nudged their price target for AbbVie slightly higher to reflect a fair value estimate of about $245 per share, supported by updated assumptions for revenue growth, profit margins, and a modestly lower future P/E. Recent research highlights both increased price targets and more cautious views around competition and the sustainability of outperformance in key immunology drugs.내러티브 업데이트 • Jan 09
ABBV: Future Returns Will Depend On Post-Humira Immunology And Pipeline Execution
Analysts have trimmed their AbbVie fair value estimate by about $0.10 per share to roughly $244.56. This reflects a mix of slightly higher risk assumptions, modestly adjusted revenue and margin expectations, and a more balanced set of views after recent downgrades and price target changes that suggest outperformance is already well reflected in the current share price.분석 기사 • Jan 08
AbbVie's (NYSE:ABBV) Dividend Will Be Increased To $1.73
AbbVie Inc. ( NYSE:ABBV ) will increase its dividend from last year's comparable payment on the 17th of February to...내러티브 업데이트 • Dec 21
ABBV: Future Returns Will Hinge On Post-Humira Immunology And Pipeline Execution
Analysts have nudged our AbbVie fair value estimate slightly higher, from $243.55 to $244.68. This reflects modestly stronger long term revenue growth expectations for key immunology franchises and pipeline assets, partially offset by slightly lower margin assumptions and a broadly constructive but mixed backdrop of recent price target revisions and rating changes across the Street.내러티브 업데이트 • Dec 07
ABBV: Future Performance Will Depend On Extended Exclusivity And Pipeline Execution
Analysts have nudged their average price target on AbbVie modestly higher to reflect a wave of target increases into the mid 240s to low 260s dollar range, supported by stronger visibility into Skyrizi and Rinvoq driven growth, extended Rinvoq exclusivity, and a more favorable large cap biopharma backdrop despite mixed ratings changes. Analyst Commentary Recent research paints a generally constructive picture on AbbVie, with most price target revisions skewing higher even as some firms move to the sidelines.분석 기사 • Dec 02
AbbVie (NYSE:ABBV) Is Increasing Its Dividend To $1.73
The board of AbbVie Inc. ( NYSE:ABBV ) has announced that it will be paying its dividend of $1.73 on the 17th of...내러티브 업데이트 • Nov 23
ABBV: Future Performance Will Depend On Pipeline Expansion And Patent Protections
AbbVie’s analyst price target has increased modestly from $241.29 to $243.55. Analysts cite resilient performance in immunology products, extended Rinvoq exclusivity, and improving fundamentals as key drivers of sentiment.분석 기사 • Nov 18
AbbVie's (NYSE:ABBV) Dividend Will Be Increased To $1.73
The board of AbbVie Inc. ( NYSE:ABBV ) has announced that it will be paying its dividend of $1.73 on the 17th of...내러티브 업데이트 • Nov 08
ABBV: Future Performance Will Reflect Balance Between Patent Wins and Product Pressures
AbbVie's analyst price target has risen modestly from $237.48 to $241.29. Analysts cite resilient fundamentals and long-term patent settlements, which help offset recent industry downgrades and softer performance in some business units.내러티브 업데이트 • Oct 25
Continued Expansion in Neuroscience and Immunology Will Drive Leadership Beyond 2025
AbbVie's analyst price target has been raised from approximately $233 to $237 per share. Analysts cite ongoing revenue growth, improved margins, and extended exclusivity for key products as the main drivers behind the upward revision.내러티브 업데이트 • Oct 11
Expanding Immunology And Neuroscience Will Reshape Global Healthcare
AbbVie's analyst price target has increased significantly, rising from $227 to $233 per share. Analysts cite recent positive developments in patent settlements and stronger-than-expected performance across key growth drivers as the main rationales.내러티브 업데이트 • Sep 27
Expanding Immunology And Neuroscience Will Reshape Global Healthcare
AbbVie’s consensus price target has been raised from $217.45 to $227.22, as analysts highlight the value added by the extended Rinvoq patent runway, top- and bottom-line beats, pipeline expansion through the Bretisilocin acquisition, and underappreciated royalty streams. Analyst Commentary Bullish analysts cite a substantial extension of Rinvoq’s U.S. patent runway through favorable settlement, delaying generic entry until 2037—4 years beyond prior expectations—and modeling this as adding $11-$24 per share in value.내러티브 업데이트 • Sep 12
Expanding Immunology And Neuroscience Will Reshape Global Healthcare
AbbVie's price target was raised to $217.45 as analysts cited the value impact of extended Rinvoq exclusivity from litigation settlement, strong Q2 results, and positive pipeline developments, outweighing near-term Aesthetics headwinds. Analyst Commentary Bullish analysts cite the settlement of litigation regarding generic Rinvoq, extending market exclusivity in the U.S. to 2037 and reducing threats from earlier-than-anticipated generic competition.주주 수익률
| ABBV | US Biotechs | US 시장 | |
|---|---|---|---|
| 7D | -4.1% | 1.2% | 2.1% |
| 1Y | 9.2% | 41.9% | 30.6% |
수익률 대 산업: ABBV은 지난 1년 동안 41.9%의 수익을 기록한 US Biotechs 산업보다 저조한 성과를 냈습니다.
수익률 대 시장: ABBV은 지난 1년 동안 30.6%를 기록한 US 시장보다 저조한 성과를 냈습니다.
주가 변동성
| ABBV volatility | |
|---|---|
| ABBV Average Weekly Movement | 3.6% |
| Biotechs Industry Average Movement | 10.6% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.2% |
안정적인 주가: ABBV는 지난 3개월 동안 US 시장에 비해 주가 변동성이 크지 않았습니다.
시간에 따른 변동성: ABBV의 주간 변동성(4%)은 지난 1년 동안 안정적이었습니다.
회사 소개
| 설립 | 직원 수 | CEO | 웹사이트 |
|---|---|---|---|
| 2012 | 57,000 | Robert Michael | www.abbvie.com |
는 연구 기반 바이오 제약 회사로 전 세계에서 의약품 및 치료제의 연구 개발, 제조, 상용화 및 판매에 종사하고 있습니다. 자가면역질환 치료제 스카이리지, 염증성 질환 치료제 린보크, 성인 혈액암 치료제 임브루비카, 혈액암 치료제 벤클렉스타, 각종 암 치료제 엘라히어, 림프종 치료제 엡킨리, 폐암 치료제 엠렐리스 등을 공급하고 있습니다. 또한 안면 주사제, 성형 및 재생 의학, 바디 컨투어링 및 스킨케어 제품, 미간 주름, 눈가 주름, 이마 주름 및 플라티마 밴드 치료를 위한 보톡스 화장품, 관자놀이, 눈 밑, 볼, 턱, 입술 및 아래 얼굴의 볼륨 손실 치료를 위한 쥬비덤 컬렉션을 제공합니다; 정신분열증, 양극성 장애 및 우울 장애를 치료하는 브릴라(Vraylar), 파킨슨병 치료제 듀오도파, 편두통 치료제 유브렐비, 삽화성 및 만성 편두통 치료제 큐립타, 운동 변동 치료를 위한 바이알레브, 만성 편두통, 과민성 방광, 경련, 경추 긴장 이상증 및 기타 질환 치료를 위한 보톡스 테라피틱(Botox Therapeutic) 등을 보유하고 있습니다.
AbbVie Inc. 기초 지표 요약
| ABBV 기초 통계 | |
|---|---|
| 시가총액 | US$362.65b |
| 순이익 (TTM) | US$3.60b |
| 매출 (TTM) | US$62.82b |
99.7x
주가수익비율(P/E)5.7x
주가매출비율(P/S)ABBV는 고평가되어 있습니까?
공정 가치 및 평가 분석 보기순이익 및 매출
| ABBV 손익계산서 (TTM) | |
|---|---|
| 매출 | US$62.82b |
| 매출원가 | US$17.57b |
| 총이익 | US$45.25b |
| 기타 비용 | US$41.65b |
| 순이익 | US$3.60b |
최근 보고된 실적
Mar 31, 2026
다음 실적 발표일
해당 없음
| 주당순이익(EPS) | 2.03 |
| 총이익률 | 72.03% |
| 순이익률 | 5.72% |
| 부채/자본 비율 | -2,119.0% |
ABBV의 장기 실적은 어땠습니까?
과거 실적 및 비교 보기| AbbVie 배당 일정 | |
|---|---|
| 배당락일 | Apr 15 2026 |
| 배당 지급일 | May 15 2026 |
| 배당락일까지 남은 일수 | 24 days |
| 배당 지급일까지 남은 일수 | 6 days |
ABBV는 안정적으로 배당을 지급합니까?
ABBV 배당 기록 및 벤치마크 보기기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/07 04:32 |
| 종가 | 2026/05/07 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
AbbVie Inc.는 51명의 분석가가 다루고 있습니다. 이 중 29명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| David Toung | Argus Research Company |
| Emily Field | Barclays |
| Luisa Hector | Berenberg |